13F Holdings
中文EN

ACRV Acrivon Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$59.99M$63.99M$46.02M$23.95M—
SG&A expense$24.12M$25.21M$21.08M$8.71M—
Operating income-$84.11M-$89.20M-$67.10M-$32.66M-$16.18M
Pretax income-$77.83M-$80.44M———
Income tax$0————
Net income-$77.91M-$80.56M-$60.39M-$31.17M-$16.24M
EBITDA-$82.76M-$88.19M-$66.57M-$32.29M-$16.15M
EPS (basic)-2.02-2.38-2.74-7.56-9.32
EPS (diluted)-2.02-2.38-2.74-7.56-9.32
Weighted avg. shares (diluted)38.51M33.79M22.08M4.12M1.74M
Balance sheet
Cash & equivalents$41.50M$39.82M$36.02M$29.52M$99.60M
Short-term investments$77.08M$139.66M$91.44M$98.23M—
Current assets$120.44M$181.63M$129.69M$132.09M$100.41M
PP&E, net$4.89M$4.47M$3.48M$2.09M$290,000
Total assets$129.72M$196.59M$138.26M$181.23M$106.59M
Current liabilities$15.66M$17.21M$13.30M$6.52M$2.91M
Total liabilities$17.20M$19.80M$17.07M$10.75M$7.88M
Shareholders' equity$112.52M$176.79M$121.19M$170.47M-$23.81M
Shares outstanding31.65M31.23M22.52M21.92M1.77M
Cash flow statement
Operating cash flow-$63.66M-$65.67M-$42.64M-$30.12M-$13.98M
Capital expenditure$1.67M$2.77M$1.29M$2.17M$238,000
Free cash flow-$65.33M-$68.44M-$43.93M-$32.28M-$14.22M
Investing cash flow$66.10M-$51.77M$50.72M-$141.68M-$238,000
Financing cash flow-$749,000$121.03M-$1.55M$101.71M$112.22M
Depreciation & amortization$1.36M$1.01M$536,000$364,000$37,000
Stock-based compensation$14.72M$14.29M$11.62M$2.19M$497,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.